Business · 14/03/2019Updated: 10/17/2026 · 1 min read

FDA Classifies Transcranial Magnetic Stimulation System for Neurological and Psychiatric Disorders into Class II

The US Food and Drug Administration (FDA) is classifying the transcranial magnetic stimulation system for neurological and psychiatric disorders into Class II, requiring special controls to ensure safety and effectiveness. This move aims to reduce regulatory burdens and increase access to innovative devices for patients.